$JUNS

Jupiter Neurosciences (JUNS) dosed the first patient in its Phase 2a RESET trial for Parkinson’s disease, evaluating JOTROL™. The trial aims to assess safety, pharmacokinetics, and biomarkers. The company is also exploring strategic options to maximize shareholder value, with Tungsten Advisors as its advisor. Parkinson’s disease affects 1.1 million U.S. patients, with a growing market.

JUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 26, 2026, Jupiter Neurosciences, Inc. (the “Company”) entered into separate Debt Forgiveness and Release Agreements (each, a “Forgiveness Agreement” and collectively, the “Forgiveness Agreements”) with certain execu

JUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering New York, August 21, 2026 — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on central nervous system disord

Jupiter Neurosciences (JUNS) reported a Q2 2026 net loss of $2.27M, slightly wider than last year's $2.25M. Per-share loss narrowed to $4.08 from $5.09. Product revenue was $0.02M, up from zero. The company priced a $2M direct offering of 307,692 shares, expected to close August 24, 2026. Cash reserves were $1.52M as of June 30, 2026. Shares closed at $6.20, up 19.92%.

Jupiter Neurosciences (JUNS) will implement a 1-for-75 reverse stock split effective Aug. 6, 2026, after shareholder approval on July 22. The company says it aims to raise the per-share price to regain Nasdaq minimum bid compliance. Shares fall from about 57.76M to ~770,081; no fractional shares, cash paid based on Aug. 6 close.

JUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001679628 0001679628 2026-07-28 2026-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

JUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001679628 0001679628 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

IPO Edge hosted a fireside chat with Jupiter Neurosciences (Nasdaq: JUNS) CEO Christer Rosén and President Alison Silva. Jupiter said it signed a definitive licensing deal with PharmAla Biotech for perpetual exclusive U.S. rights to ALA-002, a patented MDMA formulation, worth up to $100 million with milestones. The company added ALA-002 to its Phase 2 Parkinson’s program and discussed trial and regulatory outlook.

Jupiter Neurosciences licensed exclusive US rights to MDMA-based ALA-002 from PharmAla Biotech Holdings. Jupiter will pay PharmAla $3.3M upfront ($1.5M cash, $1.8M in Jupiter stock), plus $3.3M on first Phase III patient dosing and $20M on FDA NDA approval. ALA-002 targets PTSD, anxiety and other neuropsychiatric disorders.

JUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Certain identified information marked as [****] has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the Company treats as private or confidential. STRATEGIC ASSET LICENSE AGREEMENT BETWEEN: PH